ES2972584T3 - Ensayos - Google Patents
Ensayos Download PDFInfo
- Publication number
- ES2972584T3 ES2972584T3 ES17758261T ES17758261T ES2972584T3 ES 2972584 T3 ES2972584 T3 ES 2972584T3 ES 17758261 T ES17758261 T ES 17758261T ES 17758261 T ES17758261 T ES 17758261T ES 2972584 T3 ES2972584 T3 ES 2972584T3
- Authority
- ES
- Spain
- Prior art keywords
- ligand
- thiol
- target molecule
- candidate
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003446 ligand Substances 0.000 claims abstract description 288
- 238000000034 method Methods 0.000 claims abstract description 103
- 238000006243 chemical reaction Methods 0.000 claims abstract description 98
- 125000003396 thiol group Chemical class [H]S* 0.000 claims abstract description 97
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 150000003573 thiols Chemical class 0.000 claims description 143
- 239000011541 reaction mixture Substances 0.000 claims description 84
- 230000027455 binding Effects 0.000 claims description 75
- 238000011002 quantification Methods 0.000 claims description 64
- 239000003153 chemical reaction reagent Substances 0.000 claims description 55
- 230000015572 biosynthetic process Effects 0.000 claims description 47
- 239000012634 fragment Substances 0.000 claims description 46
- 125000000524 functional group Chemical group 0.000 claims description 44
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 30
- 230000002427 irreversible effect Effects 0.000 claims description 29
- 239000003638 chemical reducing agent Substances 0.000 claims description 24
- 229960003180 glutathione Drugs 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 15
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 10
- 238000004364 calculation method Methods 0.000 claims description 10
- 239000007795 chemical reaction product Substances 0.000 claims description 10
- 108010024636 Glutathione Proteins 0.000 claims description 9
- 238000010494 dissociation reaction Methods 0.000 claims description 7
- 230000005593 dissociations Effects 0.000 claims description 7
- JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical class NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 claims description 7
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 6
- 239000012039 electrophile Substances 0.000 claims description 6
- 150000002118 epoxides Chemical class 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 5
- NLVXSWCKKBEXTG-UHFFFAOYSA-M ethenesulfonate Chemical compound [O-]S(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-M 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 239000013037 reversible inhibitor Substances 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 3
- 150000002825 nitriles Chemical class 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 2
- 102000002068 Glycopeptides Human genes 0.000 claims description 2
- 108010015899 Glycopeptides Proteins 0.000 claims description 2
- 102000011931 Nucleoproteins Human genes 0.000 claims description 2
- 108010061100 Nucleoproteins Proteins 0.000 claims description 2
- 102000007982 Phosphoproteins Human genes 0.000 claims description 2
- 108010089430 Phosphoproteins Proteins 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical class NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 claims description 2
- 229940125808 covalent inhibitor Drugs 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 239000000985 reactive dye Substances 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 2
- 101150073031 cdk2 gene Proteins 0.000 description 43
- 238000005259 measurement Methods 0.000 description 20
- 102220227475 rs1064795697 Human genes 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000012216 screening Methods 0.000 description 11
- -1 aminomethyl methyl acrylates Chemical class 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 8
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 7
- 150000003926 acrylamides Chemical class 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000002424 x-ray crystallography Methods 0.000 description 4
- ADEORFBTPGKHRP-UHFFFAOYSA-N 1-[7-(dimethylamino)-4-methyl-2-oxochromen-3-yl]pyrrole-2,5-dione Chemical compound O=C1OC2=CC(N(C)C)=CC=C2C(C)=C1N1C(=O)C=CC1=O ADEORFBTPGKHRP-UHFFFAOYSA-N 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- 241000283891 Kobus Species 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000010256 biochemical assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000007876 drug discovery Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical class COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical class BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 1
- AYDAHOIUHVUJHQ-UHFFFAOYSA-N 1-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)pyrrole-2,5-dione Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2N1C(=O)C=CC1=O AYDAHOIUHVUJHQ-UHFFFAOYSA-N 0.000 description 1
- YGIABALXNBVHBX-UHFFFAOYSA-N 1-[4-[7-(diethylamino)-4-methyl-2-oxochromen-3-yl]phenyl]pyrrole-2,5-dione Chemical compound O=C1OC2=CC(N(CC)CC)=CC=C2C(C)=C1C(C=C1)=CC=C1N1C(=O)C=CC1=O YGIABALXNBVHBX-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 101000715854 Homo sapiens Cyclin-dependent kinase 2 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102220515087 Vacuolar protein sorting-associated protein 4A_H71C_mutation Human genes 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 150000001912 cyanamides Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000054634 human CDK2 Human genes 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical class NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614152.5A GB201614152D0 (en) | 2016-08-18 | 2016-08-18 | Assay |
| PCT/GB2017/052456 WO2018033753A2 (en) | 2016-08-18 | 2017-08-18 | Assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2972584T3 true ES2972584T3 (es) | 2024-06-13 |
Family
ID=57045465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17758261T Active ES2972584T3 (es) | 2016-08-18 | 2017-08-18 | Ensayos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11415579B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3500858B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7008688B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2972584T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201614152D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018033753A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112121052B (zh) * | 2019-06-25 | 2024-10-22 | 复旦大学 | 丙烯酰基苯并氮杂䓬类化合物在制备防治血液肿瘤药物中的用途 |
| CN113387831A (zh) * | 2020-03-11 | 2021-09-14 | 苏州大学 | 酰胺类化合物及其在制备神经炎症抑制剂中的应用 |
| CN116507912A (zh) * | 2020-10-28 | 2023-07-28 | 基因泰克公司 | 用于游离硫醇检测的荧光ellman测定 |
| JP7667684B2 (ja) * | 2021-04-06 | 2025-04-23 | 株式会社日立製作所 | 検体の分析前処理方法および検体前処理装置 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| DK1337853T3 (da) * | 2000-11-21 | 2009-05-04 | Sunesis Pharmaceuticals Inc | Udvidet forankringstiltag til hurtig identifikation af ligander |
| US6887667B2 (en) * | 2000-12-28 | 2005-05-03 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Method and apparatus to identify small variations of biomolecules |
| US7672786B2 (en) * | 2003-07-02 | 2010-03-02 | Sergey Krylov | Non-equilibrium capillary electrophoresis of equilibrium mixtures (NECEEM)—based methods for drug and diagnostic development |
| AU2003270848A1 (en) | 2003-09-17 | 2005-04-27 | Sunesis Pharmaceuticals, Inc. | Identification of kinase inhibitors |
-
2016
- 2016-08-18 GB GBGB1614152.5A patent/GB201614152D0/en not_active Ceased
-
2017
- 2017-08-18 WO PCT/GB2017/052456 patent/WO2018033753A2/en not_active Ceased
- 2017-08-18 US US16/326,298 patent/US11415579B2/en active Active
- 2017-08-18 EP EP17758261.6A patent/EP3500858B1/en active Active
- 2017-08-18 ES ES17758261T patent/ES2972584T3/es active Active
- 2017-08-18 JP JP2019508836A patent/JP7008688B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190293641A1 (en) | 2019-09-26 |
| EP3500858B1 (en) | 2023-12-27 |
| WO2018033753A3 (en) | 2018-05-24 |
| GB201614152D0 (en) | 2016-10-05 |
| EP3500858A2 (en) | 2019-06-26 |
| JP7008688B2 (ja) | 2022-02-10 |
| WO2018033753A2 (en) | 2018-02-22 |
| US11415579B2 (en) | 2022-08-16 |
| JP2019526792A (ja) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2972584T3 (es) | Ensayos | |
| Liu et al. | Mass spectrometry-based protein footprinting for higher-order structure analysis: fundamentals and applications | |
| Ábrányi-Balogh et al. | A road map for prioritizing warheads for cysteine targeting covalent inhibitors | |
| Chojnacki et al. | Polyubiquitin-photoactivatable crosslinking reagents for mapping ubiquitin interactome identify Rpn1 as a proteasome ubiquitin-associating subunit | |
| Troelsen et al. | Library design strategies to accelerate fragment‐based drug discovery | |
| Gonzalez-Valero et al. | An activity-based oxaziridine platform for identifying and developing covalent ligands for functional allosteric methionine sites: redox-dependent inhibition of cyclin-dependent kinase 4 | |
| Zang et al. | Chemoselective methionine bioconjugation on a polypeptide, protein, and proteome | |
| US20090131675A1 (en) | Methods for structural analysis of proteins | |
| Reindl et al. | A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1 | |
| Brodie et al. | The novel isotopically coded short-range photo-reactive crosslinker 2, 4, 6-triazido-1, 3, 5-triazine (TATA) for studying protein structures | |
| Voice et al. | Limitations of ligand-only approaches for predicting the reactivity of covalent inhibitors | |
| Craven et al. | Multiparameter kinetic analysis for covalent fragment optimization by using quantitative irreversible tethering (qIT) | |
| Winiewska-Szajewska et al. | Differential scanning fluorimetry followed by microscale thermophoresis and/or isothermal titration calorimetry as an efficient tool for ligand screening | |
| WO2018049112A1 (en) | Protein kinase allostery sensor and methods of making and using same | |
| Wang et al. | Chemical and Biological Strategies for Profiling Protein‐Protein Interactions in Living Cells | |
| US9464311B2 (en) | Method for identifying modulators of ubiquitin ligases | |
| Goebel et al. | Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors | |
| Tan et al. | Chemical Proteomics Probes: Classification, Applications, and Future Perspectives in Proteome-wide Studies | |
| Chavas et al. | Unbiased mass spectrometry elucidation of the targets and mechanisms of activity-based probes: a case study involving sulfonyl fluorides | |
| US20250180575A1 (en) | High efficiency labels for biomolecular analysis | |
| Cheng et al. | Advances in crosslinking chemistry and proximity-enabled strategies: deciphering protein complexes and interactions | |
| Deng et al. | Visible-light responsive defluorination-acyl fluoride exchange for photoclick labeling based on phenoxazine chromophores | |
| Takechi et al. | Silyl ether enables high coverage chemoproteomic interaction site mapping | |
| JP2023548079A (ja) | 遊離チオール検出のための蛍光エルマンアッセイ | |
| Maurais | Proteomic and Chemoproteomic Strategies to Interrogate Post-Translational Modifications |